Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial (SIRONA)

A Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Efficacy of Allogeneic Human Mesenchymal Stem Cells in Patients With Metabolic Syndrome.

This is a phase 2b, randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) in subjects with metabolic syndrome and to assess the effects of LMSCs on endothelial function using several different doses.

Study Overview

• Status: Withdrawn
• Conditions: Endothelial Dysfunction; Metabolic Disease
• Intervention / Treatment: Biological: Peripheral Intravenous (IV) infusion of LMSCs

Detailed Description

This is a randomized, placebo-controlled clinical trial designed to evaluate the safety and efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) in subjects with metabolic syndrome and to assess the effects of LMSCs on endothelial function using several different doses. Following a successful run-in phase, a total of forty (40) subjects will be randomized (1:1:1:1) to receive one of three different doses of LMSCs or placebo. After randomization, baseline imaging, testing and study product infusion, subjects will be followed up at 24 hours, month 1, month 3, month 6, month 9 and month 12 post study product infusion. All endpoints will be assessed at the 3, 6 and 12 month visits which will occur 90±30 days, 180±30 days, and 365±30 days respectively from the day of the study product infusion (Day 1). For the purposes of the endpoint analysis and safety evaluations, an "intent-to-treat" study population will be utilized.

• Study Type: Interventional
• Phase: Phase 2

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 45 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Each subject must provide written informed consent.
• Each subject must be ≥45 and ≤ 85 years of age at the time of signing the Informed Consent Form.
• Each subject must have endothelial dysfunction.

• At the time of enrollment, each subject must meet at least 3 out of the 5 criteria under the harmonized definition of the metabolic syndrome, consisting of the following

  • Hypertension.
  • Elevated triglycerides.
  • Reduced high-density lipoprotein (HDL) levels.
  • Elevated fasting glucose. --Central obesity.

Exclusion Criteria:

• Be unable and/or unwilling to perform any of the assessments required for endpoint analysis.
• Have diabetic retinopathy.
• Sitting or resting systolic blood pressure >180 mm Hg or diastolic blood pressure >110 mm Hg at Screening.
• Have a resting blood oxygen saturation of <93% (measured by pulse oximetry).
• Be hypersensitive to dimethyl sulfoxide (DMSO).
• Have a history of alcohol or drug abuse within the past 24 months.
• Have been diagnosed with malignancy within the past 5 years, with the exception of curatively-treated basal cell carcinoma, melanoma in situ or cervical carcinoma.
• Be an organ transplant recipient.
• Be actively listed (or expected to be listed) for transplant of any organ.
• Have a condition that limits life expectancy to < 1 year.
• Be serum positive for HIV, hepatitis B sAG or viremic hepatitis C.
• Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraception (female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to injection).
• Have any serious comorbid illness or other condition that, in the opinion of the Investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.
• Be currently participating in an investigational therapeutic or device trial.
• Be currently participating in an investigational therapeutic or device trial, or have participated in an investigational therapeutic or device trial within the previous 30 days, or participate in any other clinical trial for the duration of the time that he or she is actively participating in this trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LMSCs 10 million IV; A total of 10 subjects will receive: A single peripheral intravenous (IV) infusion of 10 x10^6 (10 million) of LMSCs to be administered on day 1.	Biological: Peripheral Intravenous (IV) infusion of LMSCs; Peripheral Intravenous (IV) infusion of LMSCs; Other Names: Biological; LMSCs
Placebo Comparator: Placebo (Plasmalyte A,HSA) IV; 10 subjects will receive: A single peripheral intravenous (IV) infusion of Plasmalyte A containing human serum albumin (HSA) to be administered on day 1.	Biological: Peripheral Intravenous (IV) infusion of LMSCs; Peripheral Intravenous (IV) infusion of LMSCs; Other Names: Biological; LMSCs
Experimental: LMSCs 20 million IV; 10 subjects will receive: A single peripheral intravenous (IV) infusion of 20x10^6 (20 million) LMSCs to be administered on day 1.	Biological: Peripheral Intravenous (IV) infusion of LMSCs; Peripheral Intravenous (IV) infusion of LMSCs; Other Names: Biological; LMSCs
Experimental: LMSCs100 million IV; 10 subjects will receive: A single peripheral intravenous (IV) infusion of 100x10^6 (100 million) LMSCs to be administered on day 1.	Biological: Peripheral Intravenous (IV) infusion of LMSCs; Peripheral Intravenous (IV) infusion of LMSCs; Other Names: Biological; LMSCs

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Endothelial function: Changes in endothelial function as assessed by the following:	Flow-mediated vasodilation (FMD). Endothelial progenitor cell (EPC) function.	1 month post infusion

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Difference in rate of change in the metabolic syndrome as defined by the following:	Endothelial function (FMD, EPC function) Inflammatory markers (CBC with differential, TNFα, CRP, IL-1, IL-6, D-dimer, Fibrinogen) Heart function and structure (Dobutamine Stress Echocardiography) Blood pressure Lipid profile (HDL; LDL; triglycerides; cholesterol) Physical activity (6 minute walk test and CHAMPS questionnaire) Lung function (spirometry) Glycemia (hemoglobin A1c;fasting glucose; urine glucose) Weight Subject quality of life (QOL) (QOL assessments).	Baseline, 3 month, 6 month and 12 months.

Collaborators and Investigators

• Sponsor: Longeveron Inc.
• Investigators: Study Director: Anthony Oliva, PhD, Longeveron Inc.

Study record dates

Study Major Dates

• Study Start (Anticipated): December 1, 2023
• Primary Completion (Anticipated): December 1, 2023
• Study Completion (Anticipated): December 1, 2023

Study Registration Dates

• First Submitted: October 23, 2015
• First Submitted That Met QC Criteria: October 23, 2015
• First Posted (Estimate): October 27, 2015

Study Record Updates

• Last Update Posted (Estimate): February 16, 2023
• Last Update Submitted That Met QC Criteria: February 14, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Metabolic Diseases
• Other Study ID Numbers: 00-0000-02

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No